1. Home
  2. CGEN vs CLAR Comparison

CGEN vs CLAR Comparison

Compare CGEN & CLAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEN
  • CLAR
  • Stock Information
  • Founded
  • CGEN 1993
  • CLAR 1957
  • Country
  • CGEN Israel
  • CLAR United States
  • Employees
  • CGEN N/A
  • CLAR N/A
  • Industry
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • CLAR Recreational Games/Products/Toys
  • Sector
  • CGEN Health Care
  • CLAR Consumer Discretionary
  • Exchange
  • CGEN Nasdaq
  • CLAR Nasdaq
  • Market Cap
  • CGEN 167.4M
  • CLAR 136.3M
  • IPO Year
  • CGEN 2000
  • CLAR N/A
  • Fundamental
  • Price
  • CGEN $1.73
  • CLAR $3.51
  • Analyst Decision
  • CGEN
  • CLAR Strong Buy
  • Analyst Count
  • CGEN 0
  • CLAR 4
  • Target Price
  • CGEN N/A
  • CLAR $5.50
  • AVG Volume (30 Days)
  • CGEN 265.3K
  • CLAR 149.3K
  • Earning Date
  • CGEN 08-05-2025
  • CLAR 07-31-2025
  • Dividend Yield
  • CGEN N/A
  • CLAR 2.84%
  • EPS Growth
  • CGEN N/A
  • CLAR N/A
  • EPS
  • CGEN N/A
  • CLAR N/A
  • Revenue
  • CGEN $27,589,000.00
  • CLAR $255,437,000.00
  • Revenue This Year
  • CGEN N/A
  • CLAR N/A
  • Revenue Next Year
  • CGEN $173.80
  • CLAR $4.23
  • P/E Ratio
  • CGEN N/A
  • CLAR N/A
  • Revenue Growth
  • CGEN N/A
  • CLAR N/A
  • 52 Week Low
  • CGEN $1.13
  • CLAR $3.02
  • 52 Week High
  • CGEN $2.66
  • CLAR $6.83
  • Technical
  • Relative Strength Index (RSI)
  • CGEN 57.84
  • CLAR 54.60
  • Support Level
  • CGEN $1.62
  • CLAR $3.51
  • Resistance Level
  • CGEN $1.81
  • CLAR $3.62
  • Average True Range (ATR)
  • CGEN 0.08
  • CLAR 0.10
  • MACD
  • CGEN -0.00
  • CLAR -0.00
  • Stochastic Oscillator
  • CGEN 65.22
  • CLAR 45.16

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About CLAR Clarus Corporation

Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and United States.

Share on Social Networks: